-
Part 2 | Session 5 SOUL: Semaglutide in Patients with T2D
-
Part 2 | Session 6 BHF PROTECT-TAVI: Cerebral Embolic Protection in TAVI
-
Part 3 | Session 1 The Phase 3 REVERSE-IT Trial
-
Part 3 | Session 2 EVOLUT Low Risk: 5Y Outcomes After TAVR or SAVR in Low-Risk Patients with AS
-
Part 3 | Session 3 SMART-CHOICE 3: Clopidogrel vs Aspirin Monotherapy in High-Risk PCI Patients
-
Part 3 | Session 6 MIGHTy-Heart: Mobile Integrated Health in Heart Failure
-
Part 3 | Session 10 Lifetime Benefit by Control of Modifiable Risk Factors
-
Part 3 | Session 11 CardiAMP-HF: Autologous Cell Therapy in Patients With HFrEF
-
Part 4 | Session 1 4 Trials That Will Change My Practice with Dr Ambarish Pandey
-
Part 4 | Session 2 4 Trials That Will Change My Practice with Dr Dipti Itchhaporia
-
Part 1 | Session 1 View from the Thoraxcenter: What's Hot at ACC.25?
-
Part 1 | Session 2 View from the Thoraxcenter: ACC 25 Wrap-Up
-
Part 2 | Session 1 ADVANCE-HTN: Lorundrostat in Patients with Uncontrolled Hypertension
-
Part 2 | Session 2 STRIDE: Semaglutide for Functional Capacity in Patients with T2D and PAD
-
Part 2 | Session 3 API-CAT: Reduced Vs Full Dose Apixaban for Cancer-Associated Thrombosis
ACC 25 - FRESH-UP shows liberal fluid intake did not result in a significant difference in health status compared to fluid restriction of 1500ml per day, but did result in a lower perceived thirst distress.
Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Roland Van Kimmenade (Radboud University Medical Center, Nijmegen, NL) to discuss the findings from the multi-center, randomized FRESH-UP Trial (NCT04551729) investigating whether fluid restriction impacts quality of life in chronic heart failure patients. The study enrolled 504 participants across eight centers in the Netherlands, who were randomized 1:1 to either follow a restricted fluid intake of 1500cc per day, or maintain a liberal fluid intake for three months.
The primary outcome measure was quality of life, measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at three months. Secondary outcomes included thirst distress, and KCCQ subscores. KCCQ-OSS at three months was 74.0 in the liberal fluid intake group, compared to 72.2 in the fluid restriction group, with a mean difference of 2.17 (95% CI -0.06-4.39; P=0.06).
Findings of the study suggest that liberal fluid intake does not harmfully impact heart failure patients, questioning the need for fluid restriction amongst patients with stable, symptomatic chronic heart failure.
Recorded Remotely from Hamilton and Maastricht, 2025.
Editors: Yazmin Sadik, Jordan Rance
Videographers: Dan Brent, David Ben-Harosh
Support: This is an independent interview produced by Radcliffe Cardiology.
Keep up-to-date with our video collection on the American College of Cardiology's 74th annual congress, covering late-breaking science, featured science and clinical horizon sessions. Don't miss the preview and wrap-up of the congress in our View From the Thoraxcenter series, concise Expert Interviews with select faculty offering take-home messages for practice, and our Highlights summarising the most influential trials.
More from this programme
Part 1
View From the Thoraxcenter
Part 2
Late-Breaker Discussion Series
Part 3
Expert Interviews
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an internationally known cardiologist, research methodologist, and senior scientist. She serves as an Associate Professor of Medicine at McMaster University, a Senior Scientist at the Population Health Research Institute, and Director of Implementation Science at the Baim Institute for Clinical Research in Boston.
Academic history
Dr Van Spall completed her BSc and MD at the University of Toronto, followed by residency and fellowship training in internal medicine and…
Comments